Community-acquired pneumonia is a leading cause of hospitalization, mortality and incurs significant health care costs. As disease presentation varies from a mild illness that can be managed as an outpatient to a severe illness requiring treatment in intensive care unit, determining the appropriate level of care is important for improving outcomes in addition to early diagnosis and appropriate and timely treatment.
The pathogens causing community-acquired pneumonia can be classified as two types: (1) Typical agents such as Staphylococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, S. aureus, Group A streptococci, anaerobes, and gram-negative organisms and (2) Atypical agents such as Legionella, Mycoplasma, Chlamydia pneumoniae, and C. psittaci. Influenza and noninfluenza respiratory viruses have been increasingly detected as pathogens depending on the availability of polymerase chain reaction-based detection methods. Worldwide, S. pneumoniae and H. influenzae are the leading causes of bacterial pneumonia. The most common pathogens identified in the most recent population-based active surveillance in the United States were human rhinovirus, influenza virus, and Streptococcus pneumoniae.
The estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the United States, the annual incidence is 24.8 cases per 10,000 adults with higher rates as age increases. Pneumonia is the eighth leading cause of death and first among infectious causes of death. The mortality rate is as high as 23% for patients admitted to the intensive care unit. All patients with comorbid illness are considered at risk for pneumonia, but specific risk factors exist for specific pathogens including (1) Drug-resistant pneumococci - age greater than 65, exposure to children in day care centers, intake of beta-lactam in previous 90 days, alcoholism, chronic medical conditions, immune-suppression; and (2) Pseudomonas - bronchiectasis, malnutrition, corticosteroid therapy, antibiotic intake for greater than 7 days in the preceding month. Other etiological clues from epidemiology include the following: coccidioidomycosis in the Southwestern United States, blastomycosis or histoplasmosis in the states of the Ohio River valley, bird exposures for Chlamydia psittaci, contact with flea-infested or infected rodent or rabbits during outside activities such as lawn mowing in the Northeast US (Martha's Vineyard, Cape Cod, etc) for tularemia pneumonia.
Colonization of the pharynx with pathogens, followed by micro-aspiration is the mechanism of entry into the lower respiratory tract. In the interaction between the pathogen and host pulmonary defense, pneumonia results if there is a defect in host defense or it is overcome by high inoculum or virulence of the pathogen. Hematogenous spread and macro-aspiration are other mechanisms.
Fever, chills, cough productive of purulent sputum, dyspnea, pleuritic chest pain, and weight loss are common symptoms. The elderly, patients with alcoholism, and those who are immune-compromised can have less evident or systemic symptoms such as weakness, lethargy, altered mental status, dyspepsia or other upper gastrointestinal symptoms, and absence of fever. Some manifestations provide etiological clues such as diarrhea, headache and confusion (related to hyponatremia) for Legionella; and otitis media, Stevens-Johnson syndrome, or anemia/jaundice (hemolytic anemia) for Mycoplasma. Pneumonia can result in acute decompensation of underlying chronic illness like congestive heart failure which can confound the initial presentation and result in diagnosis and treatment delays.
A complete blood count with differentials, serum electrolytes, and renal and liver function tests are indicated for confirming evidence of inflammation and assessing severity. A chest x-ray will be needed to identify an infiltrate or effusion, which if present, will improve diagnostic accuracy. In hospitalized patients, blood and sputum cultures should be collected, preferably before the institution of antimicrobial therapy but without delay in treatment. Urine for Legionella and pneumococcal antigens must be considered as they aid in diagnosis when cultures are negative. In the presence of confounding co-morbidities, such as congestive heart failure, serum procalcitonin levels can be used as a biomarker to initiate and guide antimicrobial therapy. Influenza testing is recommended during the winter season. If available, testing for respiratory viruses on nasopharyngeal swabs by molecular methods can be considered. CURB 65 (confusion, urea greater than or equal to 20 mg/dL, respiratory rate greater than or equal to 30/min, blood pressure systolic less than 90 mmHg or diastolic less than 60 mmHg) and Pneumonia Severity Index (PSI) are tools for severity assessment to determine the treatment setting, such as outpatient versus inpatient, but accuracy is limited when used alone or in the absence of effective clinical judgement. Serology for tularemia, endemic mycoses or C. psittaci can be sent in the presence of epidemiologic clues.
For outpatients, monotherapy with a macrolide (erythromycin, azithromycin or clarithromycin) or doxycycline is recommended. In the presence of co-morbid illness (chronic heart disease excluding hypertension; chronic lung disease - COPD and asthma; chronic liver disease; chronic alcoholism; diabetes mellitus; smoking; splenectomy; HIV or other immunosuppression) a respiratory fluoroquinolone (high-dose levofloxacin, moxifloxacin, gemifloxacin) or a combination of oral beta-lactam (high dose amoxicillin or amoxicillin-clavulanate, cefuroxime, cefpodoxime) and macrolide is recommended.
For patients with CURB 65 score of greater than or equal to 2, inpatient management is recommended. A respiratory fluoroquinolone monotherapy or combination therapy with beta-lactam (cefotaxime, ceftriaxone, ampicillin-sulbactam or ertapenem) and macrolide are recommended options for nonintensive care settings.
Admission to the intensive care unit must be considered in patients with three or more signs of early deterioration. These include respiratory rate greater than 30, PaO2/FiO2 less than or equal to 250, multilobar infiltrates, encephalopathy, thrombocytopenia, hypothermia, leucopenia, and hypotension. Combination therapy with a beta-lactam and either a macrolide or a respiratory fluoroquinolone is recommended. In patients with possible aspiration, ampicillin-sulbactam or ertapenem can be used. Monotherapy is not recommended.
If risk factors for pseudomonas are present, then anti-pseudomonal beta-lactam (piperacillin-tazobactam, cefepime, ceftazidime, meropenem, imipenem) along with either an anti-pseudomonal fluoroquinolone (ciprofloxacin or levofloxacin) or a combination of aminoglycoside and azithromycin are recommended. Vancomycin or linezolid should be added if community-acquired methicillin-resistant S. aureus is a consideration.
The recommended duration of therapy is 5 to 7 days in patients with a favorable clinical response such as the absence of fever for more than 48 to 72 hours, not requiring supplemental oxygen, and resolution of tachycardia, tachypnea, or hypotension. Prolongation of therapy is indicated in patients with a delayed response, certain bacterial pathogens such as Pseudomonas (14 to 21 days) or S. aureus (7 to 21 days) or Legionella pneumonia (14 days), and for complications such as empyema, lung abscess, or necrotizing pneumonia. Chest tube placement will be needed to drain an empyema, and in cases with multiple loculations, a surgical decortication may be needed. A 14-day therapy with macrolide or doxycycline will treat tularemia pneumonia or psittacosis, and itraconazole is the drug of choice for pneumonia caused by coccidioidomycosis or histoplasmosis.
A five-day therapy with oseltamivir is recommended for all patients who test positive for influenza virus. For outpatients with delayed presentation (greater than 48 hours from onset of symptoms), there is no benefit, but any hospitalized patients with influenza must be treated with this agent irrespective of time of presentation from the onset of illness.
Intravenous glucocorticoids can be considered in critically ill patients with community-acquired pneumonia without risk factors for adverse outcomes from use of steroids (e.g., influenza infection).
All adults 65 years and older and those considered at risk for pneumonia must receive the pneumococcal vaccination. There are two vaccines available: PPSV 23 and PCV 13.
Current ACIP recommendations for unvaccinated non-immune-compromised individuals aged 19to 64 years old and at risk for pneumonia, first should receive PPSV 23. After age 65, a dose of PCV 13 can be given (after at least one year of the first dose of PPSV 23), followed by the second dose of PPSV 23 spaced at least one year from PCV 13 and 5 years from the first dose of PPSV 23. For patients who are immune-compromised or asplenic (functional or anatomical) and 19 to 64 years old, first give PCV 13, followed by the first dose of PPSV 23 8 weeks or later and second dose PPSV 23 after 5 years. A booster PPSV 23 can be given for a patient 65 years or older after at least 5 years or longer from the second dose of PPSV 23.
For all unvaccinated adults 65 years or older, first vaccinate with PCV 13, followed by PPSV 23 at least a year later for patients who are immune competent and at least 8 weeks or more apart for patients who are immune compromised or asplenic.
Influenza vaccination is recommended for all adult patients at risk for complications from influenza. Inactivated flu shots (trivalent or quadrivalent, egg-based or recombinant) are usually recommended for adults. Live attenuated intranasal vaccine can be given to healthy, nonpregnant adults who are less than 49 years old. It is contraindicated in pregnancy, the immune suppressed or health care workers caring for them, and in those with comorbidities.
Patients with community pneumonia may present to the primary care provider, nurse practitioner, or the emergency department. Hence these professionals should be aware of the signs and symptoms. If the diagnosis is not clear cut, then an infectious disease consult is recommended. Most patients do respond to outpatient antibiotic therapy for 5-7 days. Patients who are short of breath, febrile, and in respiratory distress need to be admitted. Some patients may present with a parapneumonic effusion, which may require drainage. The primary care provider and nurse practitioner should encourage all seniors to get the annual flu vaccine. In addition, all adults 65 years and older and those considered at risk for pneumonia must receive the pneumococcal vaccination. The outcomes in most patients with community-acquired pneumonia are excellent. (Level V)
|||Lu H,Zeng N,Chen Q,Wu Y,Cai S,Li G,Li F,Kong J, Clinical prognostic significance of serum high mobility group box-1 protein in patients with community-acquired pneumonia. The Journal of international medical research. 2019 Feb 7; [PubMed PMID: 30732500]|
|||Hassen M,Toma A,Tesfay M,Degafu E,Bekele S,Ayalew F,Gedefaw A,Tadesse BT, Radiologic Diagnosis and Hospitalization among Children with Severe Community Acquired Pneumonia: A Prospective Cohort Study. BioMed research international. 2019; [PubMed PMID: 30729128]|
|||Alshahwan SI,Alsowailmi G,Alsahli A,Alotaibi A,Alshaikh M,Almajed M,Omair A,Almodaimegh H, The prevalence of complications of pneumonia among adults admitted to a tertiary care center in Riyadh from 2010-2017. Annals of Saudi medicine. 2019 Jan-Feb; [PubMed PMID: 30712048]|
|||Guo Q,Song WD,Li HY,Zhou YP,Li M,Chen XK,Liu H,Peng HL,Yu HQ,Chen X,Liu N,Lü ZD,Liang LH,Zhao QZ,Jiang M, Scored minor criteria for severe community-acquired pneumonia predicted better. Respiratory research. 2019 Jan 31; [PubMed PMID: 30704469]|
|||Torres A,Chalmers JD,Dela Cruz CS,Dominedò C,Kollef M,Martin-Loeches I,Niederman M,Wunderink RG, Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive care medicine. 2019 Jan 31; [PubMed PMID: 30706119]|
|||Pickens CI,Wunderink RG,Pickens CI, Principles and Practice of Antibiotic Stewardship in the ICU. Chest. 2019 Jan 25; [PubMed PMID: 30689983]|
|||Nuttall JJC, Current antimicrobial management of community-acquired pneumonia in HIV-infected children. Expert opinion on pharmacotherapy. 2019 Jan 21; [PubMed PMID: 30664362]|
|||Froes F,Pereira JG,Póvoa P, Outpatient management of community-acquired pneumonia. Current opinion in pulmonary medicine. 2018 Dec 24; [PubMed PMID: 30585861]|
|||Mi X,Li W,Zhang L,Li J,Zeng L,Huang L,Chen L,Song H,Huang Z,Lin M, The drug use to treat community-acquired pneumonia in children: A cross-sectional study in China. Medicine. 2018 Nov; [PubMed PMID: 30431600]|
|||Hagel S,Moeser A,Pletz MW, [Management of community acquired pneumonia]. MMW Fortschritte der Medizin. 2018 Nov; [PubMed PMID: 30406515]|
|||Espinoza R,Silva JRLE,Bergmann A,de Oliveira Melo U,Calil FE,Santos RC,Salluh JIF, Factors associated with mortality in severe community-acquired pneumonia: A multicenter cohort study. Journal of critical care. 2018 Nov 22; [PubMed PMID: 30502687]|